Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world

Imagem de Miniatura
Arquivos
art_BARACIOLI_Safety_and_efficacy_of_prasugrel_compared_with_clopidogrel_2012.PDF (392.09 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
RUFF, Christian T.
GIUGLIANO, Robert P.
ANTMAN, Elliott M.
MURPHY, Sabina A.
LOTAN, Chaim
HEUER, Herbertus
Bela Merkely
SCHERSTEN, Fredrik
SEABRO-GOMES, Ricardo
Citação
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.155, n.3, p.424-429, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Among patients with acute coronary syndrome(ACS), demographics, procedural characteristics and adjunctive medications differ globally. We examined whether there were differential effects of prasugrel compared with clopidogrel in the multinational TRITON-TIMI 38 study. Methods: We divided the enrollment into 5 pre-specified geographic regions. Patients were randomized to prasugrel or clopidogrel without regard to country of enrollment. End points are expressed as Kaplan-Meier failure estimates through 15 months. Heterogeneity was evaluated using Cox proportional hazards model. Additional sensitivity analyses were performed by dividing countries into categories based on the Human Development Index (HDI), which is a composite measure of social and economic development. Results: 13,608 patients were enrolled. Clinical characteristics including age, comorbidities, ACS presentation, stent types, and adjunctive medications differed broadly among regions. Despite these differences, no regional heterogeneity was observed with prasugrel compared to clopidogrel in the reduction of ischemic events (HR range: 0.76-0.87, p(interaction)>0.10 for each) and stent thrombosis (HR range: 0.34-0.72, p(interaction)>0.10 for each) or in the increased rate of non-CABG TIMI major bleeding (HR range: 1.16-1.76, p(interaction)>0.10 for each). There was a consistent trend in net clinical benefit (all cause death/MI/stroke/non-CABG TIMI major bleeding) favoring prasugrel (HR range: 0.81-0.97, p(interaction)>0.10 for each). Consistent results were also observed regarding the safety and efficacy of prasugrel compared with clopidogrel in both developed and developing countries. Conclusions: Despite differences in patient demographics, procedural techniques and adjunctive medications, consistent reduction in ischemic events and increased bleeding were seen with prasugrel compared with clopidogrel throughout the world.
Palavras-chave
Prasugrel, Clopidogrel, TRITON-TIMI 38, Regional differences, HDI
URI
https://observatorio.fm.usp.br/handle/OPI/1519
Referências
  1. Alexander KP, 1998, J AM COLL CARDIOL, V32, P2023, DOI 10.1016/S0735-1097(98)00466-5
  2. Anderson Jeffrey L, 2007, J Am Coll Cardiol, V50, pe1, DOI 10.1016/j.jacc.2007.02.013
  3. Antman EM, 2008, CIRCULATION, V117, P296, DOI 10.1161/CIRCULATIONAHA.107.188209
  4. BARBASH GI, 1993, J AM COLL CARDIOL, V21, P281
  5. Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161
  6. Budaj A, 2003, AM HEART J, V146, P999, DOI 10.1016/S0002-8703(03)00509-X
  7. Chang WC, 2005, J EPIDEMIOL COMMUN H, V59, P427, DOI 10.1136/jech.2004.024984
  8. Coats AJS, 2009, INT J CARDIOL, V131, P149, DOI 10.1016/j.ijcard.2008.11.048
  9. Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702
  10. Cohen MG, 2001, AM HEART J, V141, P391, DOI 10.1067/mhj.2001.113216
  11. Fox KAA, 2000, EUR HEART J, V21, P1433, DOI 10.1053/euhj.1999.1983
  12. Fu YL, 2000, CIRCULATION, V102, P1375
  13. Giugliano RP, 2001, EUR HEART J, V22, P1702, DOI 10.1053/euhj.2001.2583
  14. Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929
  15. Gupta M, 2003, EUR HEART J, V24, P1640, DOI 10.1016/S0195-668X(03)00433-0
  16. Gurfinkel EP, 2003, HEART, V89, P1083, DOI 10.1136/heart.89.9.1083
  17. King SB, 2008, CIRCULATION, V117, P261, DOI 10.1161/CIRCULATIONAHA.107.188208
  18. Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731
  19. Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171
  20. Mega JL, 2009, CIRCULATION, V119, P2553, DOI 10.1161/CIRCULATIONAHA.109.851949
  21. Moise P, 2003, OECD STUDY CROSS NAT, P70
  22. O'Shea JC, 2001, AM HEART J, V141, P866, DOI 10.1067/mhj.2001.114982
  23. O'Shea JC, 2001, AM HEART J, V141, P875, DOI 10.1067/mhj.2001.115186
  24. O'Shea JC, 2000, EUR HEART J, V21, P1397, DOI 10.1053/euhj.2000.2121
  25. Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232
  26. Silber S, 2005, EUR HEART J, V26, P804, DOI 10.1093/eurheartj/ehi138
  27. Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227
  28. TOPOL E, 1993, NEW ENGL J MED, V329, P673
  29. United Nations Development Program, 2011, HUM DEV IND
  30. Van de Werf F, 2008, EUR HEART J, V29, P2909, DOI 10.1093/eurheartj/ehn416
  31. VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586
  32. Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327
  33. Wiviott SD, 2008, CIRCULATION, V118, P1626, DOI 10.1161/CIRCULATIONAHA.108.791061
  34. Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482
  35. Wiviott SD, 2006, AM HEART J, V152, P627, DOI 10.1016/j.ahj.2006.04.012
  36. World Health Organization, 2000, WORLD HLTH REP 2000, P21
  37. [Anonymous], HIST HUM DEV REP
  38. 1998, N ENGL J MED, V339, P436

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor